Page last updated: 2024-10-20

urea and Schizophrenia

urea has been researched along with Schizophrenia in 33 studies

pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.

Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.

Research Excerpts

ExcerptRelevanceReference
"The ADVANCE study was a phase 2, 26-week, randomised, double-blind, placebo-controlled study of pimavanserin in stable outpatients with schizophrenia aged 18-55 years with predominant negative symptoms."9.51Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. ( Abbs, B; Arango, C; Bugarski-Kirola, D; Fava, M; Liu, IY; Nasrallah, H; Stankovic, S, 2022)
"These preliminary data show that urea appears to be an effective therapeutic approach for the polydipsiahyponatremia syndrome."9.11Treatment of the polydipsia-hyponatremia syndrome with urea. ( Decaux, G; Musch, W; Verhoeven, A, 2005)
" One such possible agent is the non-dopaminergic antipsychotic pimavanserin, an inverse agonist of serotonin 5-HT2A receptors which was recently approved for the hallucinations and delusions of Parkinson's Disease Psychosis."7.91Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. ( Fedora, R; Morton, R; Nasrallah, HA, 2019)
"The ADVANCE study was a phase 2, 26-week, randomised, double-blind, placebo-controlled study of pimavanserin in stable outpatients with schizophrenia aged 18-55 years with predominant negative symptoms."5.51Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. ( Abbs, B; Arango, C; Bugarski-Kirola, D; Fava, M; Liu, IY; Nasrallah, H; Stankovic, S, 2022)
"These preliminary data show that urea appears to be an effective therapeutic approach for the polydipsiahyponatremia syndrome."5.11Treatment of the polydipsia-hyponatremia syndrome with urea. ( Decaux, G; Musch, W; Verhoeven, A, 2005)
" This review provides an overview of 5-HT receptor pharmacology and discusses two recent 5-HT receptor subtype-selective drugs, lorcaserin and pimavanserin, which target the 5HT2C and 5HT2A receptors and provide new treatments for obesity and Parkinson's disease psychosis, respectively."4.89Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. ( Meltzer, HY; Roth, BL, 2013)
"Pimavanserin tartrate is the first 5-HT(2A) inverse agonist to enter clinical trials as a treatment for L-dopa-induced psychosis in Parkinson's disease and for augmentation of low-dose risperidone treatment in schizophrenia."4.84Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. ( Abbas, A; Roth, BL, 2008)
" One such possible agent is the non-dopaminergic antipsychotic pimavanserin, an inverse agonist of serotonin 5-HT2A receptors which was recently approved for the hallucinations and delusions of Parkinson's Disease Psychosis."3.91Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. ( Fedora, R; Morton, R; Nasrallah, HA, 2019)
" phencyclidine (PCP), produces prolonged impairment of novel object recognition (NOR), suggesting they constitute a hypoglutamate-based model of cognitive impairment in schizophrenia (CIS)."3.81Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats. ( Horiguchi, M; Meltzer, HY; Miyauchi, M; Oyamada, Y; Rajagopal, L, 2015)
"N-methyl-D-aspartate (NMDA) receptor open channel blockers phencyclidine (PCP) and dizocilpine (MK-801) elicit schizophrenia-like symptoms in humans and in animal models."3.74Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors. ( Deutsch, SI; Kozikowski, AP; Krolikowski, KA; Long, K; Mastropaolo, J; Monteiro, AC; Neale, JH; Olszewski, RT; Wegorzewska, MM; Zhou, J, 2008)
"Phencyclidine (PCP) administration elicits positive and negative symptoms that resemble those of schizophrenia and is widely accepted as a model for the study of this human disorder."3.72NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. ( Barton, FB; Bukhari, N; Bzdega, T; Kozikowski, AP; Neale, JH; Olszewski, RT; Shamimi-Noori, S; Vicini, S; Wroblewska, B; Wroblewski, JT; Zhou, J, 2004)
"risperidone (RIS), produce more extensive blockade of brain serotonin (5-HT)(2A) than dopamine (DA) D(2) receptors."2.77Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. ( Elkis, H; Hacksell, U; Meltzer, HY; Peters, P; van Kammen, DP; Vanover, K; Weiner, DM, 2012)
" By measuring the brain function using computer period analysis of cerebral biopotentials, dose-efficacy relations were found (in the range of 25-75 mcg) which suggest the bioavailability of LHM at the CNS level."2.64Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmaco-electroencephalogram. ( Akpinar, S; Herrmann, WM; Itil, TM, 1975)
"Pimavanserin is an antipsychotic with a unique mechanism of action (5-HT2A receptor inverse agonist) and no measurable dopaminergic activity; it has been demonstrated to be efficacious, well tolerated and safe for the treatment of PDP."2.53Pimavanserin for the treatment of Parkinson's disease psychosis. ( Chendo, I; Ferreira, JJ, 2016)
" Further study is needed to determine whether these results concerning mechanism and dosage can be the basis for prevention of the development of CIS in at risk populations."1.38Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist. ( Adelekun, AE; Hannaway, KE; Horiguchi, M; Jayathilake, K; Meltzer, HY, 2012)

Research

Studies (33)

TimeframeStudies, this research(%)All Research%
pre-199011 (33.33)18.7374
1990's1 (3.03)18.2507
2000's9 (27.27)29.6817
2010's11 (33.33)24.3611
2020's1 (3.03)2.80

Authors

AuthorsStudies
Bugarski-Kirola, D1
Arango, C1
Fava, M1
Nasrallah, H1
Liu, IY1
Abbs, B1
Stankovic, S1
Nasrallah, HA1
Fedora, R1
Morton, R1
Meltzer, HY4
Roth, BL2
Oyamada, Y1
Horiguchi, M2
Rajagopal, L1
Miyauchi, M1
Chendo, I1
Ferreira, JJ1
Abbas, A1
Bach, DR1
Herdener, M1
Grandjean, D1
Sander, D1
Seifritz, E1
Strik, WK1
Kawai, N1
Ishikawa, K1
Nemoto, K1
Katano, T1
Takahashi, S1
Hori, T1
Asada, T1
Baig, BJ1
Whalley, HC1
Hall, J1
McIntosh, AM1
Job, DE1
Cunningham-Owens, DG1
Johnstone, EC1
Lawrie, SM1
Profaci, CP2
Krolikowski, KA2
Olszewski, RT4
Neale, JH4
Marquis, KL1
Comery, TA1
Jow, F1
Navarra, RL1
Grauer, SM1
Pulicicchio, C1
Kelley, C1
Brennan, JA1
Roncarati, R1
Scali, C1
Haydar, S1
Ghiron, C1
Terstappen, GC1
Dunlop, J1
Ebdrup, BH1
Rasmussen, H1
Arnt, J1
Glenthøj, B1
Hannaway, KE1
Adelekun, AE1
Jayathilake, K1
Janczura, KJ1
Ball, SR1
Madore, JC1
Lavin, KM1
Lee, JC1
Lee, MJ1
Der, EK1
Hark, TJ1
Farago, PR1
Bzdega, T2
Elkis, H1
Vanover, K1
Weiner, DM1
van Kammen, DP1
Peters, P1
Hacksell, U1
Edoute, Y1
Davids, MR1
Johnston, C1
Halperin, ML1
FAURE, H1
TSAUNE, MK1
BRUNE, GG1
HOHL, HH1
HIMWICH, HE1
CALWELL, WP1
JACOBSEN, M1
SKARBEK, A1
GALLANT, DM2
BISHOP, MP2
SPREHE, D1
SHELTON, W1
Bukhari, N1
Zhou, J2
Kozikowski, AP2
Wroblewski, JT1
Shamimi-Noori, S1
Wroblewska, B1
Vicini, S1
Barton, FB1
Jones, HM1
Brammer, MJ1
O'Toole, M1
Taylor, T1
Ohlsen, RI1
Brown, RG1
Purvis, R1
Williams, S1
Pilowsky, LS1
Verhoeven, A1
Musch, W1
Decaux, G1
Wegorzewska, MM1
Monteiro, AC1
Long, K1
Mastropaolo, J1
Deutsch, SI1
Poyurovsky, M1
Weizman, R1
Weizman, A1
Tsygankov, BD1
Goldman, MB1
Robertson, GL1
Luchins, DJ1
Hedeker, D1
Gründig, E1
Weiss, J1
Itil, TM1
Herrmann, WM1
Akpinar, S1
Laithwaite, JA1
Berkó, G1
Durkó, I1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia[NCT02970305]Phase 2403 participants (Actual)Interventional2016-11-04Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Clinical Global Impression of Schizophrenia Scale-Improvement (CGI-SCH-I) of Negative Symptoms Score at Week 26

The CGI-SCH-I is a clinician-rated, 7-point scale to evaluate change from baseline in positive, negative, depressive, cognitive symptoms and overall severity in schizophrenia. For the purpose of this study, only the changes in negative symptoms from baseline were evaluated. The score could range from 1 (very much improved) to 7 (very much worse). (NCT02970305)
Timeframe: From baseline to Week 26

Interventionscore on a scale (Mean)
Pimavanserin3.1
Placebo3.1

Proportion of CGI-SCH-I Responders (CGI-SCH-I Score of 1 or 2) at Week 26; Observed Cases

"The CGI-SCH-I is a clinician-rated, 7-point scale that is designed to evaluate change from baseline in positive, negative, depressive, cognitive symptoms and overall severity in schizophrenia. For the purpose of this study, only the changes in negative symptoms from baseline were evaluated. The 7-point scores range from 1 (very much improved) to 7 (very much worse); responders were defined as those with CGI-SCH-I of 1 or 2.~The analysis includes observed cases; missing cases were not imputed." (NCT02970305)
Timeframe: From baseline to Week 26

InterventionParticipants (Count of Participants)
Pimavanserin47
Placebo40

Change From Baseline (CFB) to Week 26 in NSA-16 Domain Scores

The NSA-16 is a semi-structured interview and a validated scale containing 16 items for evaluating negative symptoms of schizophrenia, i.e. the reduction or absence of emotional expression and volitional behaviors normally present in a healthy person. Items are scored based on behaviors during the interview (items 1-4, 6, 7, 9, 11, 15, 16) or previous 7 days (items 5, 8, 10, 12-14) on a 6-point scale from 1 to 6. The NSA-16 domain scores are the sum of item scores in each domain i.e. communication (min score 4, max score 24), emotion/affect (min 3, max 18), social involvement (min 3, max 18), motivation (min 4, max 24), and retardation (min 2, max 12); with higher scores denoting more severe negative symptoms in schizophrenia. (NCT02970305)
Timeframe: From baseline (BL) to Week 26

,
Interventionscore on a scale (Mean)
Communication, BLCommunication, CFB to Week 26Emotion/affect, BLEmotion/affect, CFB to Week 26Social Involvement, BLSocial Involvement, CFB to Week 26Motivation, BLMotivation, CFB to Week 26Retardation, BLRetardation, CFB to Week 26
Pimavanserin12.3-2.412.7-1.913.1-2.016.7-2.67.0-1.7
Placebo12.3-2.012.5-1.612.6-1.416.6-2.27.0-1.5

Change From Baseline (CFB) to Week 26 in PANSS Subscale Scores

The PANSS is a 30-item scale to evaluate the presence, absence, and severity of schizophrenia symptoms. Items are scored over the past week (7 days) on a 7-point scale from 1 (absent) to 7 (extreme). The PANSS has 3 subscales that are the sums of the respective item scores, including the positive scale (min 7, max 49), negative scale (min 7, max 49), and general psychopathology scale (min 16, max 112). Higher scores denote more severe symptoms. (NCT02970305)
Timeframe: From baseline (BL) to Week 26

,
Interventionscore on a scale (Mean)
Positive subscale, BLPositive subscale, CFB to Week 26Negative subscale, BLNegative subscale, CFB to Week 26General psychopathology subscale, BLGeneral psychopathology subscale, CFB to Week 26
Pimavanserin13.1-0.627.5-4.036.6-4.1
Placebo13.7-0.827.5-3.838.2-4.0

Change From Baseline to Week 26 in 10-item Drug Attitude Inventory (DAI-10) Score

"The DAI-10 contains 6 items (1, 3, 4, 7, 9, and 10) that a subject who is fully adherent to the prescribed medication would answer as True and 4 items (2, 5, 6, and 8) that a subject who is fully adherent to the prescribed medication would answer as False. A correct answer is scored +1 and an incorrect answer is scored -1. The total score is the sum of pluses and minuses, which can range from -10 to 10 in increments of 2. A positive total score indicates a positive subjective response (adherent) and a negative total score indicates a negative subjective response (non-adherent). Higher scores denote better adherence." (NCT02970305)
Timeframe: From baseline to Week 26

,
Interventionscore on a scale (Mean)
BaselineChange from baseline to Week 26
Pimavanserin5.70.2
Placebo5.70.2

Change From Baseline to Week 26 in Brief Assessment of Cognition in Schizophrenia (BACS) Composite Score

The BACS is a performance-based assessment of treatment-related changes in cognition, assessing 6 domains of verbal memory and learning; working memory; motor function; verbal fluency; attention and speed of processing; and executive function. The 6 domains with their raw scores are: verbal memory 0-75; digit sequencing 0-28; token motor 0-100; verbal fluency 0-225; symbol coding 0-110; Tower of London 0-22. For each domain, higher scores reflect better cognition. Raw scores are converted to age and sex-corrected normalized scores. The BACS composite score is calculated as the mean of the normalized scores from the 6 subscale scores, standardized so that the mean of the BACS composite score in the healthy normative sample is 50 and the standard deviation is 10. (NCT02970305)
Timeframe: From baseline to Week 26

,
Interventionscore on a scale (Mean)
BaselineChange from baseline to Week 26
Pimavanserin22.943.33
Placebo20.994.16

Change From Baseline to Week 26 in Karolinska Sleepiness Scale (KSS) Score

The KSS is a self-reported subjective measure of a subject's level of drowsiness. Respondents must choose statements that most accurately describe their level of sleepiness over the past 7 days. Scoring was based on a 9-point verbally anchored scale ranging from 1 (extremely alert) to 9 (very sleepy, great effort to keep awake, fighting sleep). Higher scores denoted more drowsiness. (NCT02970305)
Timeframe: From baseline to Week 26

,
Interventionscore on a scale (Mean)
BaselineChange from baseline to Week 26
Pimavanserin4.6-0.3
Placebo4.8-0.6

Change From Baseline to Week 26 in NSA-16 Global Negative Symptoms Rating

The global negative symptoms rating of the NSA-16 assesses overall severity on a 7-point scale from 1 to 7, with higher scores denoting more severe negative symptoms in schizophrenia. (NCT02970305)
Timeframe: From baseline to Week 26

,
Interventionscore on a scale (Mean)
BaselineChange from baseline to Week 26
Pimavanserin4.7-0.7
Placebo4.8-0.7

Change From Baseline to Week 26 in the Clinical Global Impression of Schizophrenia Scale-Severity (CGI-SCH-S) of Negative Symptoms Score

The CGI-SCH-S is a clinician-rated, 7-point scale to evaluate positive, negative, depressive, cognitive symptoms and overall severity in schizophrenia. For the purpose of this study, only the negative symptoms were evaluated. The score could range from 1 (normal, not ill) to 7 (among the most severely ill). (NCT02970305)
Timeframe: From baseline to Week 26

,
Interventionscore on a scale (Mean)
BaselineChange from baseline to Week 26
Pimavanserin4.6-0.6
Placebo4.7-0.6

Change From Baseline to Week 26 in the Negative Symptom Assessment-16 (NSA-16) Total Score

The NSA-16 is a semi-structured interview and a validated scale containing 16 items for evaluating negative symptoms of schizophrenia, i.e. the reduction or absence of emotional expression and volitional behaviors normally present in a healthy person. Items are scored based on behaviors during the interview (items 1-4, 6, 7, 9, 11, 15, 16) or previous 7 days (items 5, 8, 10, 12-14) on a 6-point scale from 1 to 6. The NSA-16 total score is the sum of item scores. It can range from 16 to a maximum of 96, with higher scores denoting more severe negative symptoms in schizophrenia. (NCT02970305)
Timeframe: From baseline to Week 26

,
Interventionscore on a scale (Mean)
BaselineChange from baseline to Week 26
Pimavanserin61.8-10.5
Placebo61.0-8.8

Change From Baseline to Week 26 in the Personal and Social Performance Scale (PSP) Score

"The PSP is a validated 100-point (1 to100) single-item rating scale to assess the psychosocial functioning of subjects with schizophrenia. Ratings are based on 4 main areas i.e. (a) socially useful activities, including work and study; (2) personal and social relationships, (3) self-care; and (4) disturbing and aggressive behaviors. The time period assessed is past month. Higher scores denote better psychosocial functioning" (NCT02970305)
Timeframe: From baseline to Week 26

,
Interventionscore on a scale (Mean)
BaselineChange from baseline to Week 26
Pimavanserin47.28.1
Placebo46.78.4

Change From Baseline to Week 26 in the Positive and Negative Syndrome Scale (PANSS) Total Score

The PANSS is a 30-item scale to evaluate the presence, absence, and severity of schizophrenia symptoms. Items are scored over the past week (7 days) on a 7-point scale from 1 (absent) to 7 (extreme). The PANSS total score is the sum of scores and ranges from a minimum of 30 to a maximum of 210. Higher scores denote more severe symptoms. (NCT02970305)
Timeframe: From baseline to Week 26

,
Interventionscore on a scale (Mean)
BaselineChange from baseline to Week 26
Pimavanserin77.2-8.7
Placebo79.4-8.6

Proportion of Negative Symptom Assessment-16 (NSA-16) Responders at Week 26

"The NSA-16 is a semi-structured interview and a validated scale containing 16 items for evaluating negative symptoms of schizophrenia, i.e. the reduction or absence of emotional expression and volitional behaviors normally present in a healthy person. Items are scored based on behaviors during the interview (items 1-4, 6, 7, 9, 11, 15, 16) or previous 7 days (items 5, 8, 10, 12-14) on a 6-point scale from 1 to 6. The NSA-16 total score is the sum of item scores. It can range from 16 to a maximum of 96, with higher scores denoting more severe negative symptoms in schizophrenia.~NSA-16 responders were defined as patients with at least 20, 30, 50, or 75% percentage improvement in NSA-16 total score from baseline." (NCT02970305)
Timeframe: From baseline to Week 26

,
InterventionParticipants (Count of Participants)
At least 20% improvementAt least 30% improvementAt least 50% improvementAt least 75% improvement
Pimavanserin9356214
Placebo8451162

Reviews

4 reviews available for urea and Schizophrenia

ArticleYear
Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs.
    The Journal of clinical investigation, 2013, Volume: 123, Issue:12

    Topics: Benzazepines; Diabetes Mellitus, Type 2; Heart Valve Diseases; Humans; Molecular Structure; Obesity;

2013
Pimavanserin for the treatment of Parkinson's disease psychosis.
    Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:15

    Topics: Antipsychotic Agents; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Schizophrenia; Se

2016
Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders.
    Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:18

    Topics: Clinical Trials as Topic; Humans; Molecular Structure; Parkinson Disease; Piperidines; Schizophrenia

2008
Serotonin 2A receptor antagonists for treatment of schizophrenia.
    Expert opinion on investigational drugs, 2011, Volume: 20, Issue:9

    Topics: Antipsychotic Agents; Brain; Fluorobenzenes; Humans; Phenols; Piperidines; Positron-Emission Tomogra

2011

Trials

6 trials available for urea and Schizophrenia

ArticleYear
Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.
    The lancet. Psychiatry, 2022, Volume: 9, Issue:1

    Topics: Adolescent; Adult; Double-Blind Method; Europe; Female; Humans; Male; Middle Aged; North America; Ou

2022
Oral urea treatment for polydipsia-hyponatremia syndrome in patients with schizophrenia.
    Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:5

    Topics: Administration, Oral; Adult; Humans; Hyponatremia; Male; Middle Aged; Schizophrenia; Syndrome; Thirs

2009
Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.
    Schizophrenia research, 2012, Volume: 141, Issue:2-3

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method

2012
Cortical effects of quetiapine in first-episode schizophrenia: a preliminary functional magnetic resonance imaging study.
    Biological psychiatry, 2004, Dec-15, Volume: 56, Issue:12

    Topics: Acoustic Stimulation; Adolescent; Adult; Antipsychotic Agents; Brain Mapping; Carbamide Peroxide; Ce

2004
Treatment of the polydipsia-hyponatremia syndrome with urea.
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:11

    Topics: Administration, Oral; Adult; Aged; Body Weight; Circadian Rhythm; Comorbidity; Creatine; Drinking; D

2005
Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmaco-electroencephalogram.
    International journal of clinical pharmacology and biopharmacy, 1975, Volume: 12, Issue:1-2

    Topics: Adolescent; Adult; Aged; Biological Availability; Child; Child, Preschool; Clinical Trials as Topic;

1975

Other Studies

23 other studies available for urea and Schizophrenia

ArticleYear
Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist.
    Schizophrenia research, 2019, Volume: 208

    Topics: Adult; Aged; Antipsychotic Agents; Clozapine; Delusions; Drug Resistance; Female; Hallucinations; Hu

2019
Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
    Behavioural brain research, 2015, May-15, Volume: 285

    Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Haloperidol

2015
Altered lateralisation of emotional prosody processing in schizophrenia.
    Schizophrenia research, 2009, Volume: 110, Issue:1-3

    Topics: Acoustic Stimulation; Adult; Analysis of Variance; Brain Mapping; Carbamide Peroxide; Cerebral Corte

2009
Functional magnetic resonance imaging of BDNF val66met polymorphism in unmedicated subjects at high genetic risk of schizophrenia performing a verbal memory task.
    Psychiatry research, 2010, Sep-30, Volume: 183, Issue:3

    Topics: Brain Mapping; Brain-Derived Neurotrophic Factor; Carbamide Peroxide; Cerebral Cortex; Genotype; Hum

2010
Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia.
    Psychopharmacology, 2011, Volume: 216, Issue:2

    Topics: Animals; Bridged Bicyclo Compounds; Dextroamphetamine; Disease Models, Animal; Dose-Response Relatio

2011
Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625.
    Psychopharmacology, 2011, Volume: 218, Issue:4

    Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Avoidance Learning; Cognitio

2011
Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012, Volume: 37, Issue:10

    Topics: Animals; Cognition Disorders; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Female; Halo

2012
NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia.
    Translational psychiatry, 2012, Jul-31, Volume: 2

    Topics: Analysis of Variance; Animals; Antipsychotic Agents; Dextroamphetamine; Disease Models, Animal; Dose

2012
An integrative physiological approach to polyuria and hyponatraemia: a 'double-take' on the diagnosis and therapy in a patient with schizophrenia.
    QJM : monthly journal of the Association of Physicians, 2003, Volume: 96, Issue:7

    Topics: Adult; Diabetes Insipidus; Diagnosis, Differential; Diuresis; Humans; Hyponatremia; Male; Polyuria;

2003
[Contribution to the study of catatonia].
    Le Progres medical, 1953, Feb-24, Volume: 81, Issue:4

    Topics: Body Fluids; Catatonia; Humans; Indicators and Reagents; Schizophrenia; Urea; Urine

1953
[DATA ON THE PROBLEM OF THE PRESENCE OF MACHT'S PHYTOTOXIC REACTION IN SCHIZOPHRENIC PATIENTS].
    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1963, Volume: 63

    Topics: Ammonia; Blood Proteins; Erythrocytes; Humans; Nitrogen; Plants; Schizophrenia; Urea

1963
URINARY EXCRETION OF BUFOTENIN-LIKE SUBSTANCE IN PSYCHOTIC PATIENTS.
    Journal of neuropsychiatry, 1963, Volume: 4

    Topics: 1-Propanol; Acetates; Alcohols; Alkaloids; Ammonia; Bufotenin; Chromatography; Hallucinogens; Humans

1963
A COMPARATIVE STUDY OF OXYPERTINE AND TRIFLUOPERAZINE IN CHRONIC SCHIZOPHRENIA--A NEW APPLICATION OF THE WING RATING SCALE.
    The British journal of psychiatry : the journal of mental science, 1964, Volume: 110

    Topics: Aggression; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Behavior; Blood

1964
TPS-23: A NEW THIORIDAZINE DERIVATIVE.
    Current therapeutic research, clinical and experimental, 1965, Volume: 7

    Topics: Blood Cell Count; Blood Urea Nitrogen; Drug Therapy; Electrocardiography; Humans; Liver Function Tes

1965
A PILOT TRIAL OF CI-515 IN SCHIZOPHRENIC PATIENTS.
    Current therapeutic research, clinical and experimental, 1965, Volume: 7

    Topics: Blood Cell Count; Blood Urea Nitrogen; Drug Therapy; Electrocardiography; Guanidine; Guanidines; Liv

1965
NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR.
    Journal of neurochemistry, 2004, Volume: 89, Issue:4

    Topics: Animals; Behavior, Animal; Cells, Cultured; Disease Models, Animal; Enzyme Inhibitors; Glutamate Car

2004
Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors.
    Biological psychiatry, 2008, Jan-01, Volume: 63, Issue:1

    Topics: Agonistic Behavior; Analysis of Variance; Animals; Behavior, Animal; Disease Models, Animal; Dizocil

2008
Aripiprazole's receptor pharmacology and extrapyramidal side effects.
    The American journal of psychiatry, 2008, Volume: 165, Issue:3

    Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dopamine Agonis

2008
[Modified variant of simultaneous discontinuation of psychotropic drugs (given in combination with diuretics) as a method of abrupt termination therapy for protracted episodes of schizophrenia].
    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1980, Volume: 80, Issue:5

    Topics: Acute Disease; Diuretics; Furosemide; Humans; Mannitol; Periodicity; Psychotropic Drugs; Schizophren

1980
The influence of polydipsia on water excretion in hyponatremic, polydipsic, schizophrenic patients.
    The Journal of clinical endocrinology and metabolism, 1996, Volume: 81, Issue:4

    Topics: Adult; Blood Glucose; Blood Pressure; Creatinine; Female; Humans; Hyponatremia; Male; Middle Aged; P

1996
[The influence of neuroleptic drugs on urinary excretion of non-protein nitrogen (author's transl)].
    Arzneimittel-Forschung, 1976, Volume: 26, Issue:2

    Topics: Amino Acids; Clopenthixol; Clozapine; Creatinine; Delayed-Action Preparations; Flupenthixol; Fluphen

1976
Letter: Paraquat poisoning treated with immunosuppressants and potassium aminobenzoate.
    British medical journal, 1975, Feb-01, Volume: 1, Issue:5952

    Topics: Adult; Aminobenzoates; Azathioprine; Humans; Immunoglobulin G; Immunosuppressive Agents; Male; Paraq

1975
A new possibility for the demonstration of -amino-laevulinic acid in urine on the basis of Mauzerall-Granick method.
    Clinica chimica acta; international journal of clinical chemistry, 1972, Volume: 37

    Topics: Acute Disease; Aldehydes; Animals; Benzene Derivatives; Charcoal; Humans; Levulinic Acids; Methods;

1972